Request 1 |
What criteria does the CCG use to select which inhalers should be prescribed for Asthma and COPD? |
Response 1 |
The CCG uses clinical trials to check efficacy, cost-effectiveness and ensures that the inhalers chosen will meet the requirements of patients. Secondary care, using their expertise will have input and will check that the guidelines and inhalers chosen are suitable for patients before ratification. |
Request 2 |
How does the CCG compare the cost-effectiveness , efficacy, safety and patient usability of different inhalers when selecting which COPD and Asthma inhalers should be included on its local guidance? |
Response 2 |
Cost-effectiveness, efficacy, safety are compared using clinical trial data and drug tariff prices. Patient usability is assessed using clinical experience. |
Request 3 |
Over the past three years, has the CCG introduced a planned programme of care which resulted in the medicines optimisation team, contractors or GP practices proactively reviewing patients and aligning their COPD and/or Asthma inhalers to alternative options. |
Response 3 |
Over the past three years the CCG has reviewed patients and aligned COPD and/or Asthma inhalers to more cost effective alternatives. |
Request 4 |
Please list the alternative asthma and COPD inhalers that were introduced by the CCGs medicines optimisation team, contractors or GP practices during any planned programme of care that proactively reviewed the use of asthma and/or COPD inhalers over the past 3 years . |
Response 4 |
Tiotropium HandiHaler to Braltus Patients initiated on Fluticasone/Salmeterol combination MDI started on Sirdupla |
Request 5 |
Over the past three years, has the CCG used a QIPP scheme to introduce a planned programme of care which resulted in the medicines optimisation team, contractors or GP practices proactively reviewing patients and aligning their COPD and/or Asthma inhalers to alternative options? |
Response 5 |
Tiotropium HandiHaler to Braltus Patients initiated on Fluticasone/Salmeterol combination MDI started on Sirdupla |
Request 6 |
Please list the alternative asthma and COPD inhalers that were introduced by the CCGs medicines optimisation team, contractors or GP practices when using a QIPP scheme to introduce a planned programme of care that proactively reviewed the use of asthma and/ or COPD inhalers over the past 3 years? |
Response 6 |
Tiotropium Handihaler to Braltus Patients initiated on Fluticasone/Salmeterol combination MDI started on Sirdupla |
Request 7 |
I would also like to make a request for the full name, contact number and contact email for the following roles listed below within your CCG; Chief Officer Chief Financial Officer Medicines Management Lead |
Response 7 |
Roles: Chief Officer – Mr. Chris Edwards, chris.edwards@rotherhamccg.nhs.uk Chief Finance Officer – Mrs. Wendy Allott , wendy.allott@rotherhamccg.nhs.uk Medicines Management Lead – Mr. Stuart Lakin, stuart.lakin@rotherhamccg.nhs.uk Contact number 01709 302000 |